投稿一覧に戻る
アキュセラ【4589】の掲示板 〜2015/04/28
-
4453
>>4452
承前
O'Callaghan reportedly was brought on at Sangart five years earlier to organize the company. But after the trial mishap, O'Callaghan hopped briefly to Sonrgy, which develops chemotherapy treatments for cancer, before coming to Acucela in September 2014 as COO. Sonrgy is still in business.
記事の全体の感じは、サンディエゴから流れた来たやつが、シアトルに来て何かおかしいことをしている、という、地元の業界紙記者の警告ですね。
週刊誌的な感覚で邪推すれば、アキュセラの資金が別の会社の開発資金に流れていたり、総会後に会計を調べたら使途不明金があったりといった展開も、あってもおかしくないかもしれません。
company execs（幹部たち） have been scouting for a fresh source of financing. ですからね。
高値掴み
>>4451
ここはＳＢＩとは資本系列が違うから、連合軍で検閲ではないでしょうが、他の投稿はリンクを張っているのに、なんで削除されるか不思議！
引用された部分の詳しい説明が別にあります。英語が一寸口語調で読みずらいですが。
O'Callaghan was CEO of Sangart, a San Diego biotech company. The company apparently went "missing in action" in 2013 after burning $260 million on research and development, according to biotech news site FierceBiotech. The biotech news site reported that the company's website went dark immediately after the drug trial failed. Google searches turn up no website for Sangart and there seems to be no trace of the company since then.
That happened under O'Callaghan's leadership after the company's drug, which was designed to treat trauma patients, failed in early trials.
"About all that [Sangart's] sole big investor will do is point to financial reports stating they've cut off their commitment to provide financial support to Sangart," FierceBiotech wrote, "after the last big trial ended in failure and that company execs have been scouting for a fresh source of financing."
続く